Literature DB >> 1311187

Atrial natriuretic peptide and cyclic 3'5'-guanosine monophosphate as indicators of fluid volume overload in children with chronic renal failure.

B Lettgen1, M Bald, H Valleé, K E Bonzel, W Rascher.   

Abstract

Plasma atrial natriuretic peptide (ANP) and cyclic 3'5'-guanosine monophosphate (cGMP) were investigated as indicators of fluid volume overload in children and adolescents with chronic renal failure. Plasma ANP and cGMP were measured in both paediatric patients with chronic renal failure (n = 17, mean serum creatinine 371 +/- 242 mumol/l) and those with end-stage renal disease on haemodialysis (n = 18). cGMP was higher in children with chronic renal failure than in 45 healthy controls (1.0 +/- 0.4 vs 2.1 +/- 0.8 nmol/l, P less than 0.01), whereas plasma ANP was similar (26.9 +/- 9.7 vs 34.0 +/- 12.3 pmol/l). Both ANP and cGMP were markedly elevated in children with end-stage renal disease before haemodialysis and fell significantly during dialysis. During dialysis body weight decreased by 1.6 +/- 0.7 kg, corresponding to 4.5 +/- 2.1% of body weight. Plasma ANP correlated positively with plasma cGMP in haemodialysed patients (r = 0.43, P less than 0.05). Reduction in body weight and in mean arterial pressure correlated more closely with plasma ANP than with cGMP. Therefore, elevation of plasma ANP appears to indicate volume overload in children undergoing haemodialysis, but whether it can be used also in children with chronic renal failure requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311187     DOI: 10.1007/bf00856837

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

1.  Is cyclic GMP a clinically useful marker for ANF action?

Authors:  J M Heim; K Gottmann; J Weil; M C Haufe; R Gerzer
Journal:  Z Kardiol       Date:  1988

2.  Atrial natriuretic peptide in infants and children.

Authors:  W Rascher; M Bald; J Kreis; T Tulassay; U Heinrich; K Schärer
Journal:  Horm Res       Date:  1987

3.  Atrial natriuretic peptide and sodium homeostasis in chronic renal failure.

Authors:  T Tulassay; W Rascher; K Schärer
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

4.  Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure.

Authors:  W Rascher; T Tulassay; R E Lang
Journal:  Lancet       Date:  1985-08-10       Impact factor: 79.321

5.  Clinical assessment of extracellular fluid volume in hyponatremia.

Authors:  H M Chung; R Kluge; R W Schrier; R J Anderson
Journal:  Am J Med       Date:  1987-11       Impact factor: 4.965

6.  Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats.

Authors:  F C Luft; R E Lang; G R Aronoff; H Ruskoaho; M Toth; D Ganten; R B Sterzel; T Unger
Journal:  J Pharmacol Exp Ther       Date:  1986-02       Impact factor: 4.030

7.  Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues.

Authors:  S A Waldman; R M Rapoport; F Murad
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

8.  Plasma concentration of human atrial natriuretic polypeptide in patients with impaired renal function.

Authors:  Y Yamamoto; T Higa; K Kitamura; K Tanaka; K Kangawa; H Matsuo
Journal:  Clin Nephrol       Date:  1987-02       Impact factor: 0.975

9.  Plasma levels of atrial natriuretic peptide in patients with chronic renal failure.

Authors:  K Hasegawa; Y Matsushita; T Inoue; H Morii; M Ishibashi; T Yamaji
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

10.  Detection of fluid overload by plasma concentration of human atrial natriuretic peptide (h-ANP) in patients with renal failure.

Authors:  T Eisenhauer; J Talartschik; F Scheler
Journal:  Klin Wochenschr       Date:  1986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.